Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H. Inamoto T, et al. Among authors: uehara h. Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018. Dis Markers. 2018. PMID: 30026881 Free PMC article.
Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft.
Inamoto T, Taniguchi K, Takahara K, Iwatsuki A, Takai T, Komura K, Yoshikawa Y, Uchimoto T, Saito K, Tanda N, Kouno J, Minami K, Uehara H, Hirano H, Nomi H, Kiyama S, Akao Y, Azuma H. Inamoto T, et al. Among authors: uehara h. Oncotarget. 2015 Aug 28;6(25):21628-35. doi: 10.18632/oncotarget.4129. Oncotarget. 2015. PMID: 26036261 Free PMC article.
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan.
Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, Matsunaga T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Uehara H, Tanaka T, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Komura K, et al. Among authors: uehara h. Ann Surg Oncol. 2019 Sep;26(9):2994-3004. doi: 10.1245/s10434-019-07530-5. Epub 2019 Jun 25. Ann Surg Oncol. 2019. PMID: 31240592
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
Matsunaga T, Komura K, Hashimoto T, Muraoka R, Satake N, Tsutsumi T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Matsunaga T, et al. Among authors: uehara h. World J Urol. 2020 Dec;38(12):3183-3190. doi: 10.1007/s00345-020-03118-x. Epub 2020 Feb 17. World J Urol. 2020. PMID: 32065276
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. Cancers (Basel). 2021 Jul 15;13(14):3554. doi: 10.3390/cancers13143554. Cancers (Basel). 2021. PMID: 34298768 Free PMC article.
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Nishimura K, et al. Among authors: uehara h. J Immunother Cancer. 2022 Jan;10(1):e003868. doi: 10.1136/jitc-2021-003868. J Immunother Cancer. 2022. PMID: 35039462 Free PMC article.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
[Renal cell carcinoma in a horseshoe kidney: a case report].
Ibuki N, Uehara H, Komura K, Koyama K, Inamoto T, Segawa N, Tuji M, Azuma H, Katsuoka Y. Ibuki N, et al. Among authors: uehara h. Hinyokika Kiyo. 2009 Oct;55(10):611-3. Hinyokika Kiyo. 2009. PMID: 19926945 Free article. Review. Japanese.
Feasibility of photodynamic diagnosis for challenging TUR- Bt cases including muscle invasive bladder cancer, BCG failure or 2nd-TUR.
Takai T, Inamoto T, Komura K, Yoshikawa Y, Uchimoto T, Saito K, Tanda N, Kouno J, Minami K, Uehara H, Takahara K, Hirano H, Nomi H, Kiyama S, Azuma H. Takai T, et al. Among authors: uehara h. Asian Pac J Cancer Prev. 2015;16(6):2297-301. doi: 10.7314/apjcp.2015.16.6.2297. Asian Pac J Cancer Prev. 2015. PMID: 25824753 Free article.
884 results